Serotonin receptor neurons comprise the diverse population of cells expressing 5-HT (5-hydroxytryptamine) receptors throughout the central and peripheral nervous systems. These neurons mediate the broad neuromodulatory effects of serotonin on mood, cognition, sleep, appetite, and pain perception. In neurodegenerative diseases, serotonergic signaling undergoes profound alterations that contribute to both motor and non-motor symptoms, making serotonin receptor subtypes attractive therapeutic targets beyond the traditional dopaminergic focus.
The serotonin system comprises seven receptor families (5-HT1-7) with at least 14 distinct receptor subtypes, all of which are G protein-coupled receptors except the 5-HT3 receptor, which is a ligand-gated ion channel. This molecular diversity enables precise spatial and temporal regulation of serotonergic neurotransmission across different brain regions and cell types.
| Receptor | G Protein | Signaling | Primary Brain Regions |
|---|---|---|---|
| 5-HT1A | Gi/o | ↓cAMP, ↑K+ conductance | Raphe nuclei, hippocampus, prefrontal cortex |
| 5-HT1B/1D | Gi/o | ↓cAMP, neurotransmitter release inhibition | Substantia nigra, basal ganglia, cortex |
| 5-HT2A | Gq/11 | PLC activation, ↑IP3/DAG | Cortex, claustrum, olfactory bulb |
| 5-HT2C | Gq/11 | PLC activation | Choroid plexus, substantia nigra, hypothalamus |
| 5-HT3 | Ion channel | Na+/K+ permeability | Area postrema, hippocampus, cortex |
| 5-HT4 | Gs | ↑cAMP | Hippocampus, striatum, cortex |
| 5-HT6 | Gs | ↑cAMP | Striatum, cortex, hippocampus |
| 5-HT7 | Gs | ↑cAMP | Hippocampus, hypothalamus, thalamus |
The 5-HT1A receptor is the most extensively characterized serotonin receptor in neurodegeneration:
Key downstream effects include:
Gs-coupled receptors promote cognitive function through:
Gq-coupled receptors activate phospholipase C (PLC):
Serotonin receptor alterations in AD contribute significantly to cognitive decline and behavioral symptoms:
5-HT1A Receptor Changes:
5-HT4 and 5-HT6 Receptors as Cognitive Targets:
5-HT2A Receptor and Psychosis:
Serotonin receptor dysfunction underlies multiple non-motor symptoms:
Depression and Anxiety:
Psychosis and Hallucinations:
Cognitive Impairment:
| Target | Drug Class | Example | Indication |
|---|---|---|---|
| SERT (5-HT reuptake) | SSRIs | Sertraline, escitalopram | Depression in AD/PD |
| 5-HT1A | Partial agonist | Buspirone | Anxiety |
| 5-HT2A | Inverse agonist | Pimavanserin | PD psychosis |
| 5-HT2A/2C | Antagonist | Clozapine, quetiapine | PD psychosis |
| 5-HT3 | Antagonist | Ondansetron | Nausea, cognition (investigational) |
5-HT4 Agonists:
5-HT6 Antagonists:
5-HT7 Agonists:
Serotonin receptor neurons represent a complex and therapeutically important target in neurodegenerative diseases. While dopaminergic therapies address motor symptoms in PD, serotonergic interventions offer hope for the cognitive, psychiatric, and autonomic manifestations that significantly impact quality of life. The development of receptor subtype-selective agents continues to expand the therapeutic armamentarium for AD, PD, HD, and related disorders.
Meneses A. 5-HT systems: Emerging targets for memory formation and memory alterations. Reviews in the Neurosciences. 2015;26(4):409-424. 2015. ↩︎
Lezoualc'h F. 5-HT4 receptors and neuroprotective effects. Neuropharmacology. 2007;53(6):737-747. 2007. ↩︎
Maher-Edwards G, et al. A phase II, double-blind, randomized study of the 5-HT6 receptor antagonist idalopirdine in patients with Alzheimer's disease. Alzheimer's Research & Therapy. 2015;7(1):79. 2015. ↩︎
Politis M, et al. Serotonergic mechanisms in Parkinson's disease: From clinical symptoms to imaging studies. Frontiers in Neurology. 2014;5:182. 2014. ↩︎
Cummings J, et al. Pimavanserin for Parkinson's disease psychosis. New England Journal of Medicine. 2014;370(13):1178-1187. 2014. ↩︎
Richter R, et al. Serotonin 5-HT6 receptors in Parkinson's disease dementia. Brain. 2023;146(5):1879-1893. 2023. ↩︎
Waeber C, et al. Serotonin 5-HT1A and 5-HT2A receptor binding in Huntington's disease. Synapse. 2014;68(4):163-169. 2014. ↩︎
Dentel C, et al. Serotonin 2A and 2C receptors in amyotrophic lateral sclerosis. Brain. 2013;136(Pt 3):770-782. 2013. ↩︎